- Hikma’s core operating profit forecast for 2025 is between $730 million and $770 million, exceeding estimates which stood at $720.2 million.
- For the year 2024, Hikma’s core revenue was $3.16 billion, surpassing the estimate of $3.09 billion.
- Revenue from injectables was reported at $1.32 billion.
- Generics revenue reached $1.04 billion, exceeding the estimate of $997.1 million.
- Branded revenue totaled $769 million, slightly above the estimate of $765.1 million.
- Core operating profit for 2024 came in at $719 million, just below the estimated $722.5 million.
- Core EBITDA registered at $824 million for the year 2024.
- Core profit amounted to $495 million, outperforming the estimate of $490.7 million.
- A final dividend per share of 48 cents was declared.
- Basic core earnings per share (EPS) were $2.24, beating projections of $2.22.
- Analysts’ recommendations include 8 buy ratings, 4 hold ratings, and no sell ratings.
A look at Hikma Pharmaceuticals Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
When looking at the Smartkarma Smart Scores for Hikma Pharmaceuticals, it’s clear that the company has a solid outlook for the long term. With a strong momentum score of 5, Hikma Pharmaceuticals is showing positive trends that could drive its future performance. Additionally, the company scores well in both the dividend and growth categories, with scores of 3 for each. This indicates that Hikma Pharmaceuticals is likely to provide stable returns for investors while also demonstrating growth potential.
While Hikma Pharmaceuticals may have lower scores in the value and resilience categories, with scores of 2 each, its overall outlook remains positive. As a multinational pharmaceutical group with operations in key regions like the United States, the Middle East, North Africa, and Europe, Hikma Pharmaceuticals is well-positioned to benefit from a diverse market presence and a wide range of pharmaceutical products.
### Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on developing, manufacturing, and marketing a range of both branded and non-branded generic and in-licensed pharmaceutical products. The Company’s operations are conducted in the United States, the Middle East, and North Africa region, as well as Europe. ###
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
